pipette
ESEspañol

Phase 1 Study of Anito-cel, a d -Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma

Matthew J. Frigault, Binod Dhakal, Andrzej J. Jakubowiak, Noopur Raje, Kamalika Banerjee, C. Jenny Mu, Kevin C. Hart, Sigal Shachar, Lawrence Peter Andrews, Laurene S. Cheung, Faith M. Griffin, Alexandra R. Witter, Michael Hyde, Chester Pham, Nikitha Gandra, Tenzin Shakya, Bhargavi Rajan, Christa Cortesio, Samuel T. Haile, Heba Nowyhed, Priyanka Nair-Gupta, Priyam Mitra, Rebecca J. Chan, Ana Kostic, Christopher R. Heery, Jacalyn M. Rosenblatt, Michael Russell Bishop

Peer-reviewed journalReal-world use

In the authors' words

This journal does not let us republish the full abstract. Here are the two sentences Pipette selected, quoted from it. Read the rest at the publisher.

Main result
CONCLUSIONS: Anito-cel therapy led to a high incidence of response among patients with heavily pretreated relapsed or refractory multiple myeloma.

Appeared: Friday, September 25. New England Journal of Medicine. Peer-reviewed journal.

DOI: 10.1056/nejmoa2603527